Alkem Laboratories share news, announcements and annual reports
NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap
Alkem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹5,113.50up ₹34.50 (0.68%)BSE ₹5,125.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹5,079.00.
30 Oct: open ₹5,060.50, high ₹5,134.50, low ₹5,030.00
52-week range of traded prices to 30 Oct 2026
₹4,811.00Low, 22 Oct 2026₹5,933.50High, 13 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹61,140 Cr164th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.04%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,08,03658.4% delivered
Alkem Laboratories share news and announcements
794 announcements, routine notices left out, newest first. Page 15 of 16.
Feb 2018
9 Feb · Board meeting
1 Feb · Analysts
Jan 2018
Dec 2017
7 Dec · Meeting
Nov 2017
10 Nov · Results
2 Nov · Analysts
Oct 2017
Sep 2017
Aug 2017
23 Aug · News Verification
Exchange has sought clarification from Alkem Laboratories Limited with respect to recent news item captioned "Alkem Labs gets US FDA nod for rhinitis drug, Azelastine Hydrochloride Spray". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.11 Aug · Results
11 Aug · Board meeting
Jul 2017
28 Jul · Analysts
May 2017
29 May · Legal
Exchange has sought clarification from Alkem Laboratories Limited with respect to announcement dated 26-May-2017, regarding Appointment of Mr Dheeraj Sharma as Independent Director of the company w.e.f. May 26, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.26 May · Corporate action
Company has fixed Record Date as September 1, 2017 for the purpose of Annual General Meeting and payment of final dividend.26 May · Results
Apr 2017
20 Apr · Meeting
Mar 2017
Feb 2017
10 Feb · Results
Jan 2017
25 Jan · Analysts
Dec 2016